title: Vitreous web after pars plana vitrectomy and bevacizumab with fluid-air exchange.
abstract: BACKGROUND
  Intravitreal bevacizumab may result in intraocular inflammation of infectious and non-infectious etiology. Appropriate recognition of a sterile process can circumvent unnecessary treatment for endophthalmitis.
  
  
  METHODS
  Observational case report.
  
  
  METHODS
  A marked web-like inflammatory response within the vitreous following intraoperative intravitreal bevacizumab is described in a patient with pre-proliferative diabetic retinopathy, macular edema, and epiretinal membrane who underwent pars plana vitrectomy, membrane peel, endolaser, and fluid-air exchange. Wide-field fundus photography captured the full extent of this reaction.
  
  
  RESULTS
  On post-operative day one, the patient presented with vitreous opacities in the form of a web of multiple white strands inferior to an air bubble, with minimal anterior or vitreous cell. At one week, the inflammatory reaction had completely resolved.
  
  
  CONCLUSIONS
  Existing reports of intraocular inflammation following intravitreal bevacizumab range from uveitis to infectious endophthalmitis. With wide-field fundus imaging, we report an acute, marked web-like inflammatory response following intraoperative intravitreal bevacizumab that resolved spontaneously.
authors.affiliation: Department of Ophthalmology, Jules Stein Eye Institute, University of California, Los Angeles, CA 90095, USA.
authors.forename: Allen
authors.initials: A
authors.lastname: Chiang
authors.forename: Shantan
authors.initials: S
authors.lastname: Reddy
authors.forename: Irena
authors.initials: I
authors.lastname: Tsui
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Hubschman
mesh_terms: D000368:Aged; D000388:Air; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003131:Combined Modality Therapy; D003930:Diabetic Retinopathy / Q000150:complications / Q000628:therapy; D009877:Endophthalmitis / Q000139:chemically induced* / Q000175:diagnosis / Q000503:physiopathology; D019773:Epiretinal Membrane / Q000150:complications / Q000628:therapy; D005128:Eye Diseases / Q000139:chemically induced* / Q000175:diagnosis / Q000503:physiopathology; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema / Q000209:etiology / Q000628:therapy; D008297:Male; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity; D014821:Vitrectomy; D014822:Vitreous Body / Q000187:drug effects* / Q000473:pathology
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab